Tanvex Biopharma, Inc.

Tanvex Biopharma, Inc.

TTWSE:6541
26.80
TWD
-0.70
(-2.55%)
-5.59EPS
10.63BMarket Cap
Mar 10Next Earn

Total Valuation

TWD

As of June 30, 2026, Tanvex Biopharma, Inc. carries a market capitalization of 10.63B, placing it among publicly traded companies globally. Its enterprise value stands at 12.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap10.63B
Enterprise Value12.12B

Important Dates

Tanvex Biopharma, Inc.'s next confirmed earnings release is scheduled for March 10, 2027.

Earnings Date3/10/2027

Share Statistics

As of June 30, 2026, Tanvex Biopharma, Inc. has 264.99M shares outstanding.

Shares Outstanding264.99M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 15.98, and the price-to-book ratio stands at 2.14.

PS Ratio15.98
PB Ratio2.14
P/TBV Ratio6.81
P/FCF Ratio-6.01
P/OCF Ratio-11.24

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 18.43 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 12.12B versus a market cap of 10.63B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales18.43

Financial Position

As of June 30, 2026, Tanvex Biopharma, Inc. maintains a current ratio of 1.47, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 41.96, indicating elevated leverage, while an interest coverage ratio of -21.18 demonstrates limited ability to service its debt obligations.

Current Ratio1.47
Quick Ratio0.72
Debt / Equity41.96
Debt / EBITDA-1.93
Interest Coverage-21.18

Financial Efficiency

TWD

Over the twelve months ended June 30, 2026, Tanvex Biopharma, Inc. posted a negative return on equity (ROE) of -29.78, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -20.17, reflecting losses generated across the asset base. The company generates approximately 3.54M in revenue per employee across its workforce of 186.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.89 indicates how many times Tanvex Biopharma, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-29.78
Return on Assets (ROA)-20.17
Revenue Per Employee3.54M
Employee Count186.00
Inventory Turnover4.89

Taxes

TWD

Over the twelve months ended June 30, 2026, Tanvex Biopharma, Inc. recorded 31,000.00 in income tax expense. The company reported a pretax loss of -1.47B and -1.47B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax31,000.00

Stock Price Statistics

TWD

As of the close on November 17, 2026, Tanvex Biopharma, Inc.'s stock has declined approximately 51.54% over the past 52 weeks. The 50-day moving average sits at 30.29, while the 200-day moving average is 38.85.

52-Week Price Change-51.54%
50-Day Moving Average30.29
200-Day Moving Average38.85

Income Statement

TWD

Over the twelve months ended June 30, 2026, Tanvex Biopharma, Inc. generated 657.56M in revenue and converted that into -1.47B in net income, yielding earnings per share of -5.59. EBITDA reached -1.08B, while operating income came in at -1.41B.

Revenue657.56M
Gross Profit-898.48M
Operating Income-1.41B
Pretax Income-1.47B
Net Income-1.47B
EBITDA-1.08B
EBIT-1.43B
Earnings Per Share (EPS)-5.59

Balance Sheet

TWD

As of June 30, 2026, Tanvex Biopharma, Inc. holds 592.56M in cash and equivalents against 2.08B in total debt, resulting in a net debt position of 2.42M. Total book value stands at 4.97B, with working capital of 385.09M providing operational flexibility.

Cash & Cash Equivalents592.56M
Total Debt2.08B
Net Debt2.42M
Equity (Book Value)4.97B
Book Value Per Share18.74
Working Capital385.09M

Cash Flow

TWD

Tanvex Biopharma, Inc. produced -934.96M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -813.95M in capital expenditures, free cash flow totaled -1.75B - equivalent to -6.67 per share.

Operating Cash Flow-934.96M
Capital Expenditures-813.95M
Free Cash Flow-1.75B
FCF Per Share-6.67

Margins

Over the twelve months ended June 30, 2026, Tanvex Biopharma, Inc. posted a gross margin of -136.64, reflecting its pricing power and cost economics. The operating margin of -214.98 and net profit margin of -222.84 provide insight into operational efficiency.

Gross Margin-136.64
Operating Margin-214.98
Pretax Margin-222.83
Profit Margin-222.84
EBITDA Margin-164.09

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -16.64: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -15.91, meaning Tanvex Biopharma, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-15.91
FCF Yield-16.64

Stock Splits

Tanvex Biopharma, Inc.'s most recent stock split took place on July 18, 2025 with a 361:364 split ratio.

Last Split Date7/18/2025
Split Ratio361:364

Scores

As of June 30, 2026, Tanvex Biopharma, Inc. has an Altman Z-Score of -3.88, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-3.88